PROTEASE INHIBITORS

	Nucleoside and Nucleotide reserve transcriptase inhibitors		Protease inhibitors
	Non-Nucleoside reserve transcriptase inhibitors

	Mutations associated to resistance	Mutations associated to « possible resistance »
IDV	M46I/L V82A/F/S/T I84V L90M and at least 2 among : K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I	L90M
SQV	G48V I84V L90M	V82A/F/S/T and at least 2 among: I54V/L/M/T, A71V/T, G73S, V77I
NFV	D30N I84V N88S/D L90M	V82A/F/S/T and at least 2 among: L10I, M36I, M46I/L, I54V/L/M/T, A71V/T, V77I
RTV	M46I/L V82A/F/S/T I84V L90M and at least 2 among: K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I	L90M
APV	I50V At least 4 mutations among : L10I, V32I, M46I/L, I47V, I54L/M/V, G73S, V82A/F/I/T/S, I84V, L90M
APV/RTV	I50V At least 6 mutations among : L10I, V32I, M46I/L, I47V, I54L/M/V, G73S, V82A/F/I/T/S, I84V, L90M
LPV/r	At least 8 mutations among : L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M	6 or 7 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M
ATV	I50L : no enough data to provide any recommendation in Protease inhibitors experienced patients	V32I and M46I and I84V and N88S